#mtnbc
Updated 1L mTNBC recommendations from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer: Click here to see the latest 1L mTNBC treatment recommendations: https://ow.ly/VEI150ZXkRt
October 21, 2026 at 7:00 PM
As I adjust to being one of those living MTNBC, my mission is to help spread the word. Please think about supporting cancer research and the many charities who provide information and practical help to those living with cancer and their families.
Almost 1 million people are living with or beyond breast cancer in the UK. Together, they could fill London's O2 Arena 50 times.

That's 50 times too many...

That’s why we’re researching right now, to get to the day where no one dies. Help fund the research that will make it happen.
October 10, 2026 at 8:16 AM
🎙️Tune in to hear Dr. Sara Tolaney discuss new first-line treatment options for metastatic triple-negative breast cancer on the Patient From Hell podcast. #mTNBC #TNBC #BreastCancer #MBC

🎧 youtu.be/GC1Kpf3vKns?...
New First-Line Treatment: Metastatic Triple-Negative Breast Cancer with Dr. Sara Tolaney
YouTube video by Patient From Hell
youtu.be
September 3, 2026 at 6:16 PM
Read the Phase 1b/2 Study: Durvalumab + Paclitaxel ± Capivasertib or Oleclumab in mTNBC (NCT03742102), in Clinical Cancer Research. buff.ly/84bWT8W
September 3, 2026 at 1:55 PM
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer. #bcsm #oncology

www.onclive.com/view/europea...
European Commission Approves Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ mTNBC | OncLive
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.
www.onclive.com
August 24, 2026 at 2:16 PM
Excited to share my first post & see the second part of my PhD work published! Our study on mTNBC highlights that baseline clonal expansion of dysfunctional CD8 cells is linked to better response to chemoimmunotherapy.
More here: www.sciencedirect.com/science/arti...

#CD8 #TCellExhaustion #TNBC
Continuous replenishment of the dysfunctional CD8 T cell axis is associated with response to chemoimmunotherapy in advanced breast cancer
Chemotherapy combined with immune checkpoint blockade has shown clinical activity in breast cancer. Response, however, occurs in only a low proportion…
www.sciencedirect.com
March 10, 2025 at 5:54 PM
very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm
📢 Just published! A phase II study of #abemaciclib for patients with #retinoblastoma-positive, triple-negative #metastatic breast cancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39908010/
@drtimothyerick.bsky.social @nlinmd.bsky.social
@stolaney1.bsky.social
February 7, 2025 at 10:00 PM
Cancer is not cool.

#mTNBC
The cool part about cancer is all the amazing experiences you soak up that you never would have before.
June 7, 2025 at 7:51 PM
New ASCO insights are helping oncology nurses manage treatment side effects more effectively and support patients through metastatic breast cancer care.

www.oncnursingnews.com/view/nursing...

#Oncology #BreastCancer #TCSC
Nursing Insights: ASCENT-04 Results and Toxicity Management From ASCO | Oncology Nursing News
Dr. Sara Tolaney discusses the ASCENT-04 trial results for mTNBC and key strategies for oncology nurses to manage patient toxicities like diarrhea.
www.oncnursingnews.com
June 8, 2026 at 5:54 PM
Has the holy grail of curing many cancers been found? Maybe. Turning cold tumours hot. Let’s watch #$CYDY tomorrow as they released amazing abstracts today mTNBC MSs Colorectal Cancer. #cancer
March 18, 2026 at 4:01 AM
Do you know anyone with metastatic triple negative breast cancer? Hope is on the horizon with Cytodyn’s Leronlimab.
#mtnbc #cancer #breastcancer
$CYDY. More news coming soon

www.cytodyn.com/newsroom/pre...
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targe...
www.cytodyn.com
May 13, 2025 at 9:10 PM
November 23, 2024 at 10:07 PM
Dr Peter Schmid presenting on IMpassion 130 - atezolizumab is effective in the PDL1+ mTNBC subpopulation #ASCO19
November 18, 2024 at 5:24 PM
Need input from the #bcsm #oncoalert hive for a woman with metastatic TNBC who, as a consequence of tx for said mTNBC, has developed severe MDS/AML. Not eligible for stem cell transplant d/t new metastatic pleural effusion. Who is the best person/center in the US for her to see?
November 18, 2024 at 10:35 AM
#SABCS20 #metastatic #TNBC @JenniferLitton speaking - only 17% of people with mTNBC are alive 5 years after diagnosis. 😢
November 18, 2024 at 5:43 AM
ok, now it's mTNBC time: IMpassion130, atezolizumab +nab-paclitaxel vs nab-pac alone. #ASCO21 #bcsm
November 18, 2024 at 1:08 AM
Dr Claudine Isaacs summing up treatment sequencing for mTNBC #MBCRC22
November 17, 2024 at 11:26 AM